The biotinylated NPY analog functions by binding to NPY receptor subtypes (Y₁, Y₂, Y₄, Y₅) with affinity comparable to native NPY, coupling to Gi/o proteins to inhibit adenylate cyclase and reduce intracellular cAMP levels. However, its primary utility lies in its detection capabilities rather than prolonged signaling: the biotin moiety enables secondary binding to streptavidin/avidin conjugates labeled with fluorophores, enzymes, or beads for visualization and isolation purposes. The lysine linker minimizes steric interference with receptor engagement while providing efficient biotin presentation, allowing the conjugate to serve as both a receptor ligand and a detection probe without significantly altering the pharmacological profile of NPY binding.

This biotinylated NPY conjugate is indicated exclusively for research applications requiring detection and capture of NPY receptors. It is employed in receptor pull-down and immunoprecipitation assays to isolate NPY receptor complexes, immunohistochemistry and immunofluorescence for tissue localization of NPY receptors, flow cytometry for cell surface receptor detection, ELISA and Western blot applications using streptavidin-based detection systems, autoradiography and binding studies as a non-radioactive alternative, and validation of NPY receptor expression and distribution in various cell types and tissues. The product serves as a versatile detection tool for NPY receptor research but is not intended for functional signaling assays requiring sustained receptor activation or for diagnostic, therapeutic, or clinical use.

As a research detection reagent, Neuropeptide Y-Lys(Biotin), human, rat has no established clinical efficacy or safety profile for therapeutic applications. The conjugate has not undergone clinical trials, regulatory approval, or safety evaluation for any medical indication. While it contributes to fundamental understanding of NPY receptor biology through advanced detection methodologies and may inform the development of future diagnostic or therapeutic approaches targeting NPY receptors, its utility remains confined to preclinical research. Any clinical translation would require development of entirely distinct diagnostic or therapeutic agents with comprehensive preclinical and clinical testing, as this product is designed solely for research detection purposes.